Nanosonics Limited · ASX:NAN
Nanosonics — FY2015 Earnings Presentation
19 slides from Nanosonics's earnings presentation, 2015
Slide 1: Leader in Infection Control Solutions - 2015 Full Year Results
Leader in Infection Control Solutions 2015 Full Year Results Investor Presentation
Slide 2: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs o
Slide 3: Corporate Mission
Corporate Mission We improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted, and introducing innovative technologies that deliver improved standards of care. Johns Hopkins Photo Credit: American Nur
Slide 4: Company Overview
Company Overview • Proprietary automated technology for low temperature, high level disinfection • First product, trophon® EPR, for high level disinfection of ultrasound probes • Approved for sale in most major markets including: US/Canada, ANZ, Europe, Singapore, HK, South Korea, Japan • 130 Staff
Slide 5: Company Overview
Company Overview Key Corporate Data (as at 30 June 2015) $2.00 $1.90 Share price $1.70 $1.80 NAN ($) $1.70 Shares on issue 282.91 million $1.60 $1.50 Market capitalisation $481 million $1.40 $1.30 Liquidity (30 day avg) 527,000 shares $1.20 $1.10 Cash $45.7 million $1.00 $0.90 Share register Founder
Slide 6: 2015 Highlights
2015 Highlights • Ongoing strong growth in the installed base - now in excess of 5,000 in US • North American direct sales operations now established • European distribution expanded into five new countries with partner Miele Professional • Formal research conducted in Japan in preparation for marke
Slide 7: 2015 Financial Results
2015 Financial Results • Sales up 3.4% to $22.2 million – In line with plan as North American direct sales FY15 FY14 operations established $ million H1 H2 FY15 H1 H2 FY14 • Gross Profit up $1.4 million to $15.3 million Sales Revenue 14.3 7.9 22.2 9.7 11.8 21.5 • GP% up to 69% mainly due to: Gross P
Slide 8: US sales growth in line with plan
US sales growth in line with plan Sales $17.7 $17.7 • FY15 sales of $17.7 million $ million consistent with pcp due to H2 H1 $13.2 $5.6 transformation of business model $9.7 in H2 $10.2 • trophon EPR now represented in $10.1 $6.5 $12.1 44 of the top 50 hospitals and in $8.0 more than 1,500 hospitals
Slide 9: US direct sales operation
US direct sales operation • Direct sales operation covering all US territories established • 18 highly qualified sales professionals trained and focussed on building sales pipeline • Warehousing, order fulfilment and direct service fully operational • Establishing Nanosonics as leading infection pre
Slide 10: ANZ setting the benchmark for standard of care
ANZ setting the benchmark for standard of care • Sales of $2.3 million Sales $2.3 $2.3 • Installed base grew 13% and now $ million approaching 1,000 units $1.7 $1.5 • trophon EPR becoming standard of care in ANZ • Market penetration ~ 60% FY12 FY13 FY14 FY15 10
Slide 11: Europe/ROW sales growing strongly
Europe/ROW sales growing strongly • FY15 sales of $2.3 million up 45% on pcp Sales • UK primary driver of sales in the $2.3 $ million period with installed base now ~250 units across 40 sites $1.6 • New Welsh guidelines supporting trophon and guidelines in England and Scotland expected H1FY16 $0.4 •
Slide 12: New global headquarters support strategic growth objectives
New global headquarters support strategic growth objectives 12
Slide 13: Clinical research program demonstrates trophon EPR superior efficacy
Clinical research program demonstrates trophon EPR superior efficacy • Expanded efficacy testing with independent laboratories against pathogens such as HIV and Chlamydia • Study by University Hospital Munster showed 3 x higher risk of cross contamination with manual wipe method that is standard acr
Slide 14: trophon EPR first and only system to kill HPV
trophon EPR first and only system to kill HPV • 2014 study showed disinfectants commonly used on ultrasound probes not effective against human papillomavirus (HPV) • Worked with researchers at Penn State College of Medicine and Brigham Young University • Key highlight was announcement that trophon E
Slide 15: R&D investment
R&D investment • More than $5 million invested in R&D activities across mechanical, electrical and software engineering, microbiology and chemistry • Active programs underway on – Next generation trophon – New disinfectant chemistries – New decontamination devices 15
Slide 16: Compatible with more than 900 ultrasound transducer models
Compatible with more than 900 ultrasound transducer models • Expanded number of ultrasound probes approved with trophon from 600 to 900 • Covers all world’s leading manufacturers • Includes both intracavitary and surface probes 16
Slide 17: Focusing on 5 core corporate objectives
Focusing on 5 core corporate objectives Establish our offerings as new standards of care globally and Customer Experience provide customers a convenient, seamless and consistent experience with both product and brand Create and bring to market a portfolio of innovative and quality products that addr
Slide 18: Business outlook – Positioned for continued growth
Business outlook – Positioned for continued growth • Direct North American sales operations in place • Growing installed base • Expanding territories in Europe and Asia Pacific • Market fundamentals for standard of care strengthening with highly relevant clinical data • Ongoing investment in R&D 18
Slide 19: Nanosonics
narosonics (LM ine n. For Life.